Premium
Plasma fluphenazine concentrations in outpatients receiving fluphenazine decanoate (Modecate)
Author(s) -
Kimber Nigel M.,
Marriott Peter F.,
Norman Trevor R.,
Burrows Graham D.
Publication year - 1986
Publication title -
human psychopharmacology: clinical and experimental
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.461
H-Index - 78
eISSN - 1099-1077
pISSN - 0885-6222
DOI - 10.1002/hup.470010205
Subject(s) - fluphenazine , tardive dyskinesia , plasma concentration , dyskinesia , extrapyramidal symptoms , medicine , plasma levels , pharmacology , chemistry , endocrinology , schizophrenia (object oriented programming) , haloperidol , psychiatry , antipsychotic , dopamine , disease , parkinson's disease
Plasma fluphenazine concentrations were measured by neuroleptic radioreceptor assay in 17 outpatients receiving chronic treatment with intramuscular fluphenazine decanoate. The range of concentrations was 0.5–2.4 μg/L over the dosage range of 0.30–3.2 mg/d. Age, sex and smoking status had no influence on plasma fluphenazine concentrations, which were not correlated with dose (expressed as mg/kg/d). There was no significant correlation between plasma concentration and clinical status of the patients. No difference in plasma concentration between patients with extrapyramidal signs or tardive dyskinesia and those without signs were observed.